GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Appili Therapeutics Inc (OTCPK:APLIF) » Definitions » Net Income

APLIF (Appili Therapeutics) Net Income : $-2.81 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Appili Therapeutics Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Appili Therapeutics's Net Income for the three months ended in Jun. 2024 was $-1.16 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2024 was $-2.81 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Appili Therapeutics's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was $-0.01.


Appili Therapeutics Net Income Historical Data

The historical data trend for Appili Therapeutics's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Appili Therapeutics Net Income Chart

Appili Therapeutics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Income
Get a 7-Day Free Trial -3.88 -11.40 -19.84 -6.76 -2.79

Appili Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.17 -0.72 -0.11 -0.82 -1.16

Appili Therapeutics Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Appili Therapeutics's Net Income for the fiscal year that ended in Mar. 2024 is calculated as

Net Income(A: Mar. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-2.742+-0.052+0+0.00099999999999989
=-2.79

Appili Therapeutics's Net Income for the quarter that ended in Jun. 2024 is calculated as

Net Income(Q: Jun. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-1.157+0+0+0
=-1.16

Net Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Appili Therapeutics  (OTCPK:APLIF) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Appili Therapeutics's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Appili Therapeutics Net Income Related Terms

Thank you for viewing the detailed overview of Appili Therapeutics's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Appili Therapeutics Business Description

Traded in Other Exchanges
Address
1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.

Appili Therapeutics Headlines

From GuruFocus

Appili Therapeutics Announces Overnight Marketed Equity Offering

By Business Wire Business Wire 05-17-2022